MedPath

The Predictive Value of Lubricin in Patients With Infective Endocarditis

Conditions
Infective Endocarditis
Registration Number
NCT06266741
Lead Sponsor
Aydin Adnan Menderes University
Brief Summary

The main goal of this study is to evaluate the predictability of the disease by measuring the serum lubricin levels in patients with infective endocarditis and in non-patients

Detailed Description

Infective endocarditis is a challenging disease with a wide range of clinical presentations, making it difficult to diagnose. Diagnosis primarily relies on clinical suspicion based on symptoms. Blood cultures or other microbial tests confirming the presence of infection and echocardiography are supportive diagnostic tools. Another marker that may become valuable in the near future for diagnosing infective endocarditis is Lubricin. Lubricin, a glycoprotein expressed by the PRG4 gene, has been found to have significantly elevated levels in the plasma of animals with damaged or infected heart valves compared to healthy animals. Furthermore, plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection. Lubricin and Procalcitonin will be studied from the blood samples routinely collected. During this academic study, procalcitonin and lubricin values will be measured by investigators. Thus, the sensitivity and specificity of the Lubricin parameter in patients with infective endocarditis will be evaluated.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
60
Inclusion Criteria
  • The patient must be between 18 and 65 years old
  • Patients diagnosed with infective endocarditis according to the Duke criteria
Exclusion Criteria
  • The patient being pregnant

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Valve damage indicative sign in infective endocarditisthrough study completion, an average of 2 years

Concentration of Lubricin parameter have a determinative role in patients with infective endocarditis

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sevil Gulasti

🇹🇷

Aydın, Zafer, Turkey

Sevil Gulasti
🇹🇷Aydın, Zafer, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.